Adenosine 3',5'-monophosphate in cerebrospinal fluid. Effect of drugs and neurologic disease.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002526:Cerebellar Diseases / Q000188:drug therapy; D002648:Child; D000242:Cyclic AMP / Q000134:cerebrospinal fluid* / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006816:Huntington Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D009135:Muscular Diseases / Q000134:cerebrospinal fluid; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000134:cerebrospinal fluid; D011339:Probenecid / Q000627:therapeutic use*; D013118:Spinal Cord Diseases / Q000134:cerebrospinal fluid* / Q000188:drug therapy
D004295:Dihydroxyphenylalanine; D000242:Cyclic AMP; D011339:Probenecid; D006719:Homovanillic Acid